← Back to catalogue

Alt (sgpt) Liquid Reagent (kinetic Method)

FDA UDI

Class I (US FDA UDI)

by Teco Diagnostics

Identity

Trade Name
ALT (SGPT) LIQUID REAGENT (KINETIC METHOD) FDA UDI
Generic Name
Alanine aminotransferase (ALT) IVD, reagent FDA UDI
Device Name
The ALT(SGPT) Liquid Reagent (Kinetic Method) is used for the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses. FDA UDI
Model / Reference
A524-150 FDA UDI
Description
The ALT(SGPT) Liquid Reagent (Kinetic Method) is used for the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses. FDA UDI

Identifiers

Catalog Number
A524-150 FDA UDI
Primary DI / UDI-DI
10673486001082 FDA UDI
FDA Product Code
CKA FDA UDI
GMDN Term
Alanine aminotransferase (ALT) IVD, reagent FDA UDI

Classification

Device Class
Class I FDA UDI
Regulation Number
862.1030 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

No

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

Yes

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

Yes

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

Yes

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

No

FDA UDI

Expiration Date

Yes

FDA UDI

Manufacturing Date

No

FDA UDI

Category: Alanine aminotransferase (ALT) IVD, reagent

Alt (sgpt) Liquid Reagent (kinetic Method) by Teco Diagnostics — Class I — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS

Similar devices

Also classified as Alanine aminotransferase (ALT) IVD, reagent.

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Manufacturer
Teco Diagnostics

Sources (1)

  • FDA UDI e977691b-dc7f-4b26-a2e7-9f963632d3f3 36 fields · synced Jun 8, 2026